Robert Ross
Chief Executive Officer presso SURFACE ONCOLOGY, INC.
Profilo
Presently, Robert W.
Ross holds the position of President at Surface Oncology, Inc. Dr. Ross is also on the board of Xilio Therapeutics, Inc. and Obsidian Therapeutics, Inc.
Dr. Ross previously was Senior Vice President-Clinical Development at bluebird bio, Inc.
Dr. Ross received an undergraduate degree from Stanford University, a graduate degree from Harvard Medical School and a graduate degree from Columbia University College of Physicians & Surgeons.
Posizioni attive di Robert Ross
Società | Posizione | Inizio |
---|---|---|
SURFACE ONCOLOGY, INC. | Chief Executive Officer | 01/04/2021 |
XILIO THERAPEUTICS, INC. | Director/Board Member | 16/06/2022 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 03/09/2020 |
Precedenti posizioni note di Robert Ross
Società | Posizione | Fine |
---|---|---|
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/10/2016 |
Formazione di Robert Ross
Stanford University | Undergraduate Degree |
Harvard Medical School | Graduate Degree |
Columbia University College of Physicians & Surgeons | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
XILIO THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |